GlassScriptPhysician profile
Craig Alan Richman
NPI 1902806284
$2,945.22
in general payments reported to CMS, 2019-2025
22 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 81% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $83.31 · 2021: $130 · 2022: $148 · 2023: $572 · 2024: $565 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $909.88 | 2022-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $394.39 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $203.02 | 2019-2025 | |
| Glaxosmithkline, LLC. | $199.26 | 2023-2025 | Nucala |
| Genzyme Corporation | $183.96 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $167.97 | 2019-2023 | |
| Integra Lifesciences Corporation | $150.00 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aerin Medical INC. | $148.55 | 2023 | |
| Hikma Pharmaceuticals USA | $103.32 | 2022-2024 | Ryaltris |
| Smith+Nephew, INC. | $84.59 | 2019-2024 | Ent Sinus |
| Optinose US, INC. | $75.72 | 2023-2025 | |
| Amgen INC. | $70.85 | 2019-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $57.28 | 2025 | Neffy |
| Janssen Biotech, INC. | $35.56 | 2019-2021 | |
| Kaleo, INC. | $31.77 | 2023 | Auvi-Q |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $24.95 | 2024 | Sinuva |
| Olympus America INC. | $21.38 | 2021 | |
| Taiho Oncology, INC. | $19.33 | 2019 | |
| Karl Storz Endoscopy-America | $17.38 | 2021 | |
| Myriad Genetic Laboratories, INC. | $17.26 | 2021 | |
| Karyopharm Therapeutics INC. | $15.58 | 2020 | |
| Eisai INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Richman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.